Neoadjuvant Chemotherapy for the Treatment of Patients With Bladder Cancer
Alexander Kutikov, MD, FACS, attending surgeon, Urologic Oncology, associate professor, Urologic Oncology, Fox Chase Cancer Center, discusses neoadjuvant chemotherapy for the treatment of patients with bladder cancer.
Kutikov and his colleagues feel it is best for patients to be treated with chemotherapy before surgery because the surgery continues to have limitations. About 20% to 30% of patients have a chance of recurrence. Neoadjuvant chemotherapy is also recommended due to the fact that there is no significant harm for patients.
Alexander Kutikov, MD, FACS, attending surgeon, Urologic Oncology, associate professor, Urologic Oncology, Fox Chase Cancer Center, discusses neoadjuvant chemotherapy for the treatment of patients with bladder cancer.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
